Lixoft Overview
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$18.6M
Lixoft General Information
Description
Developer of a modeling and simulation platform designed to reduce the cost and increase the success rate of new drug development. The company's platform deals in model-based drug development and advances to the modeling and simulation community in user-friendly tools designed to break the preclinical/ clinical/ vigilance divide for modeling and simulation, enabling drug developers to share information and synthesize them in studies.
Contact Information
Website
www.lixoft.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Discovery Tools (Healthcare)
Parent Company
Primary Office
- 8 rue de la Renaissance
- Batiment D
- 92160 Antony
- France
+33 09 00 00 00 00
Lixoft Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 01-Apr-2020 | $18.6M | 000.00 | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 01-Jan-2010 | Completed | Startup |
Lixoft Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of a modeling and simulation platform designed to reduce the cost and increase the success rate of new drug de
Drug Discovery
Antony, France
11
As of 2020
00.00
0000-00-00
000000&0
000000
sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad mi
00000 00000000000000
Barcelona, Spain
00
As of 0000
0000000000
Add Comparison
Lixoft Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 00000000 | Corporation | Barcelona, Spain | 00 | 0000000000 |
Lixoft Patents
Lixoft Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4102511-A1 | Method for determining an effect of a drug on a patient with a specific dose regimen | Pending | 11-Jun-2021 | 000000000 | 0 |
Lixoft Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jonathan Chauvin | Chief Executive Officer | ||
| Marc Lavielle | Co-Founder, Board Member & Chief Scientist | ||
| Jérôme Kalifa Ph.D | Co-Founder & Chairman |
Lixoft Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Jérôme Kalifa Ph.D | Lixoft | Co-Founder & Chairman | 000 0000 |
| Marc Lavielle | Lixoft | Co-Founder, Board Member & Chief Scientist | 000 0000 |
Lixoft Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Lixoft Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| IncubAlliance | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |